Eli Lilly and Company LLY
Eli Lilly and Company Stock Price Chart
Eli Lilly and Company Key Statistics
Fundamentals snapshot
Wall Street analyst ratings
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well
This page tracks Eli Lilly and Company's live share price, valuation multiples and the latest news. For how we source and present market data, see our methodology.
Latest Eli Lilly and Company news
We're expanding our Eli Lilly and Company coverage. In the meantime, browse the latest stock market news and live markets.
Other Healthcare stocks
Eli Lilly and Company (LLY) FAQ
What is Eli Lilly and Company (LLY)?
Eli Lilly and Company is a publicly traded company listed on NYSE under the ticker LLY. Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well
What is the LLY stock price today?
Eli Lilly and Company (LLY) is trading at $1,105.00, down 1.93% on the day. Prices on this page update through the trading session. This is not financial advice.
Is LLY a buy?
Wall Street analysts currently rate LLY a consensus "Buy", with an average 12-month price target of $1,215.10 (+9.96% vs the current price). Ratings are opinions, not guarantees — always do your own research.
When does Eli Lilly and Company report earnings?
The next Eli Lilly and Company earnings date is around Aug 5, 2026. Earnings dates can move — check the company's investor relations page to confirm.
Does LLY pay a dividend?
Eli Lilly and Company pays a dividend with a current yield of about 0.63% ($6.92 per share annually).
Market data is provided for information only and may be delayed. Nothing on this page is investment advice or a recommendation to buy or sell LLY. Markets are volatile and investing carries risk — always do your own research.